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 Detection of Small Changes in Psoriasis 
Intensity with PrecisePASI 
 Antonios G.A. Kolios a, b    Lars E. French a    Alexander A. Navarini a  
 Departments of  a  Dermatology and  b  Immunology, University Hospital of Zurich,  Zurich , Switzerland 
riasis. Nowadays it is used in most studies to measure 
treatment response. PASI has the drawback of being in-
sensitive to milder changes, especially in the lower re-
gions (PASI <10)  [2] . This occurs because PASI uses a 
discontinuous score from 0 to 6 to grade area involve-
ment rather than the actual percentages of area involve-
ment ( fig. 1 ). If the area of involvement changes within 
an area score interval, i.e. from 1% increasing to 9% which 
are both graded as area involvement of ‘1’, the PASI re-
mains unchanged due to its calculation.
 In addition, the reproducibility of PASI has been criti-
cized repeatedly  [2–5] due to inter-observer variation, 
overestimation of the involved areas by untrained observ-
ers  [6, 7] as well as its non-linear scale and lack of sensi-
tivity at the lower end of its range  [4] .
 However, as PASI is the gold standard of measurement 
of psoriasis disease activity, we did not seek to create a 
new score, but rather to improve sensitivity in the lower 
range of body surface area (BSA) by using a novel method 
of calculating the PASI score. PrecisePASI is calculated 
with the exact percentage of area involvement and may 
thus reflect small changes in surface involvement more 
accurately  [8] .
 For milder psoriasis, PASI is rarely used and no single 
score of choice has been earmarked. To maintain compat-
ibility with the wealth of earlier studies using PASI whilst 
improving precision in the range of BSA <10%, the vali-
dated clinical procedure of PASI measurement is applied 
with the actual percentage of area involvement instead of 
the imprecise area classes intervals  [6, 9–11] .
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 Abstract 
 Background: The Psoriasis Area and Severity Index (PASI) is 
the score of choice to grade psoriasis severity and detect 
clinical changes. Due to low resolution based on the calcula-
tion of the score by fixed area classes, PASI scores <10 have 
little value.  Methods: At 756 patient examinations, psoriasis 
activity was measured with both PASI and PrecisePASI.  Re-
sults: PrecisePASI has a linear increase while PASI has a stair-
case pattern. Both scores meet at the endpoint-relevant val-
ues of body surface area (BSA) 10, 30, 50, 70 and 90%. PASI 
and PrecisePASI correlate significantly over the whole range 
of BSA. In the region of BSA <5%, PrecisePASI shows a sig-
nificantly higher resolution (p < 0.0001).  Conclusion: The cal-
culation of PrecisePASI corrects the undesired inaccuracies 
of PASI in the lower BSA ranges and is a tool to use as an 
endpoint in trials aiming to detect differences in the lower 
ranges of BSA.  © 2015 S. Karger AG, Basel 
 Introduction 
 Since its original publication in 1978  [1] , the Psoriasis 
Area and Severity Index (PASI) has become an important 
and irreplaceable tool for grading disease severity in pso-
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 Methods 
 We collected PASI, PrecisePASI and BSA at 756 patient exam-
inations in 328 different patients (222 male, 106 female, mean age 
± standard deviation [SD] 49.7 ± 15.4 years) during the time from 
May 2011 until February 2012. Patients with any kind of psoriasis 
affecting the skin and any kind of medication (topical, systemic or 
both) were included in the analysis. Non-plaque psoriasis cases 
were excluded. As the original PASI uses area classes (1: 0% to 
<10%; 2:  ≥ 10% to <30%; 3:  ≥ 30% to <50%; 4:  ≥ 50% to <70%;
5:  ≥ 70% to <90%; 6:  ≥ 90% to 100%;  fig. 1 ), we integrated the per-
centage of affected BSA measured by patients’ palm evaluation  [12] . 
During the data collection, two dermatologists (A.A. Navarini, 
A.G.A. Kolios) independently measured both scores. Subsequently, 
a single consensus value was agreed upon and saved in the elec-
tronic patient registry. PrecisePASI was calculated using the same 
clinical criteria as PASI concerning erythema, scaling and infiltra-
tion, but instead of using area scores, the exact percentage of area 
involvement was utilized ( fig. 2 ). The data were anonymized and 
analyzed with permission of the institutional review board.
 Results 
 As shown in  figure 1 , PASI follows a ‘staircase pattern’ 
due to the area class and stays on a certain value until the 
next area class is reached although BSA is increasing. In-
stead, PrecisePASI scores increase linearly upon enlarge-
ment of area involvement while still overlapping with 
PASI at BSA 10, 30, 50, 70 and 90% ( fig. 1 ). These points 
correspond to the lower thresholds of the six original 
PASI area classes  [1] .
 Below a BSA of 5%, PASI scores tend to be higher than 
PrecisePASI measurements (see  table  1 for descriptive 
statistics and differences). In the region of BSA <2%, PASI 
was up to a PASI value of 4.72 higher than PrecisePASI 
(mean of differences 0.87). With an increasing BSA of  ≥ 2 
to <5%, the difference decreased (mean of differences 
0.37). In the region of BSA  ≥ 5 to <10% instead, PASI was 
up to a PASI value of 5.42 lower than the calculation with 
actual percentages (mean of differences –0.14). Compar-
ing PrecisePASI and PASI in the whole BSA range from 
0 to 100%, 756 patient examinations were included, with 
a mean PrecisePASI of 5.23 (SD ±6.47) and a mean PASI 
of 5.24 (SD ±7.11) with a mean of the difference of –0.01 
(95% confidence interval (CI) –0.09 to 0.07, p = 0.79, not 
significant), which was explainable due to reciprocal 
compensation with positive values in BSA ranges <5% 
and negative values in BSA ranges >5%. Hence over the 
whole range of BSA, PrecisePASI and PASI correlated 
significantly (p < 0.0001, Pearson correlation 0.9902, 95% 
CI 0.9887–0.9915) ( fig. 3 ).
 In 19 of 756 cases, the results of both scores were dis-
cordant around the threshold of 10, which can be relevant 
for therapeutic decisions. The distribution of results was 
analyzed in detail. In 18 patients PrecisePASI was be-
tween 10.1 and 13.41 (11.19 ± 0.79) while the correspond-
ing PASI showed a value between 8.7 and 9.9 (9.27 ± 
0.36), and in one patient PASI was at 10.1 and Precise-
PASI at 9.88. For statistical analysis GraphPad Prism Ver-
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 Fig. 1. Discontinuous increase in the area score in the normal PASI 
system versus the continuous increase in the PrecisePASI system 
for erythema, infiltration and desquamation of 1-1-1, 2-1-2 and 
4-4-4 (staircase pattern and boundary points). 
 Table 1.  Descriptive statistics and differences
BSA PE Mean
PASI
SD Min. Max. Mean
PrecisePASI
SD Min. Max. Mean of
difference
95% CI p
value
p value
summary
<2% 204 1.47 1.14 0.00 6.40 0.60 0.60 0.00 6.40 0.87 0.76 to 0.98 <0.0001 ****
≥2% to <5% 192 2.65 1.24 0.20 6.80 2.29 1.09 0.20 5.60 0.37 0.28 to 0.46 <0.0001 ****
≥5% to <10% 165 4.99 2.36 0.80 14.60 5.14 2.49 0.76 14.60 –0.14 –0.25 to –0.03 0.01 **
0 – 100% 756 5.23 6.47 0.00 59.40 5.24 7.11 0.00 60.50 –0.01 –0.09 to 0.07 0.79 n.s.
 PE = Patient examinations; Min. = minimum; Max. = maximum. 
Level of significance: n.s. = not significant; ** p ≤ 0.01; **** p ≤ 0.0001.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
19
8.
14
3.
58
.1
 - 
11
/2
5/
20
15
 1
0:
51
:3
7 
AM
 Kolios/French/Navarini
 
 Dermatology 2015;230:314–317 
DOI: 10.1159/000371811
316
sion 5 (GraphPad Software Inc., La Jolla, Calif., USA) was 
used. The paired double-sided t test was used for analysis 
of BSA, PASI and PrecisePASI and the Pearson test for 
correlation analysis.
 Conclusion 
 PrecisePASI demonstrates an improved method to 
objectively measure and study mild psoriasis and its 
therapy in the lower BSA ranges. Several valid approach-
es to improve PASI have been published, though few are 
widely used and compatible with the original PASI  [13–
15] . In a systematic review by Puzenat et al.  [4] , PASI 
overall is rated as the gold standard concerning content 
validity and has good rates in internal consistency and 
intra-observer variation as well as acceptable rates in in-
ter-observer variation and sensitivity to change. Com-
pared to other scores, the PASI still satisfies the greatest 
number of validation criteria. The assessment of out-
come measurements included the following key criteria: 
construct validity (Is the score able to study the dis-
ease?), content validity (Are the items of the score rep-
resentative for the disease?), internal consistency (Are 
the various items of the score non-redundant?), intra-
observer variation (Do two independent evaluations by 
the same observer give the same result?), inter-observer 
variation (Do two independent observers give the same 
score?), sensitivity to change (Can the score detect 
changes in the course of the disease?) and acceptability 
(Can the score be applied in routine practice/in clinical 
trials?)  [4] . As PrecisePASI is a calculatory adaptation of 
PASI using identical clinical data, we assumed that the 
validity of PASI applied equally for both scores. During 
the data collection a consensus was made from two in-
dependent analyses of two dermatologists. This method 
did not allow to gauge reproducibility and variability of 
PrecisePASI, which will be evaluated in subsequent 
studies.
 PASI and PrecisePASI scores match closely at crucial 
points and correlate significantly over the whole range of 
BSA (p < 0.0001;  table 1 ,  fig. 3 ). Below a BSA of 5% PASI 
is higher than PrecisePASI, which could be interpreted as 
an overestimation of disease activity (p < 0.0001 for mean 
of difference), whereas in the region of BSA  ≥ 5 to <10% 
PASI is lower than PrecisePASI, which could be inter-
preted as underestimation of disease activity (p = 0.01 for 
mean of difference).
0.1 * (Eh + Ih + Dh) * IF(Ah <10; Ah*0.2; IF(Ah >89;6;(Ah –10)*0.05 + 2)) Head
+0.3 * (Et + It + Dt) * IF(At <10; At*0.2; IF(At >89;6;(At –10)*0.05 + 2)) Trunk
+0.2 * (Eu + Iu + Du) * IF(Au <10; Au*0.2; IF(Au >89;6;(Au –10)*0.05 + 2)) Upper extremity
+0.4 * (EL + IL + DL) * IF(AL <10; AL*0.2; IF(AL >89;6;(AL –10)*0.05 + 2)) Lower extremity
Area
grading
Erythema
Infiltration
Desquamation
Exact area calculation:
If BSA <10% => factor 0.2 is added
If BSA ≥10% => factor 0.05 is added
IF(A >89;6;formula) means that when A >89 is fulfilled, the result is 6, 
otherwise the formula is calculated
 Fig. 2. PrecisePASI formula. 
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 Fig. 3. Correlation of PASI and PrecisePASI (p < 0.0001, Pearson 
correlation 0.9902, 95% CI 0.9887–0.9915). 
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 As nowadays patients with severe psoriasis are in gen-
eral well-treated, we need an advanced but backward-
compatible tool to gauge psoriasis activity in the lower 
ranges. The PrecisePASI method detects changes in the 
course of the disease in the lower BSA ranges. Thus, it is 
more sensitive in detecting change than PASI, a feature 
that may represent an advantage compared to the original 
PASI calculation.
 Since the exact percentages of area involvement are 
recorded in PrecisePASI, it can be easily transformed to 
the normal PASI. In the online supplementary data (www.
karger.com/doi/10.1159/000371811), a Microsoft Excel ® 
sheet that we use at our clinic to simultaneously calculate 
both PASI scores is available for download (online suppl. 
table 1).
 Treatment studies aiming to improve psoriasis in the 
lower PASI ranges may have difficulty demonstrating ef-
fects because the PASI score is relatively insensitive to 
detect improvements at BSA <10% ( table 1 ). Using Pre-
cisePASI, these limitations could be overcome. In addi-
tion, with a higher resolution in lower BSA ranges, Pre-
cisePASI might also display more precisely the total im-
provement of moderate-to-severe psoriasis both in 
clinical care and trials. We propose that in future studies, 
especially with mild psoriasis, PrecisePASI be used as a 
secondary endpoint together with the normal PASI.
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